China to open borders for patients travelling for medical treatment

Medical visa to China
China to open its borders for the first time since COVID pandemic outbreak. Borders will open for all types of visa. Check how to obtain medical visa for China. Visa-free entry will also resume for Hainan Island and Shanghai-bound cruise ships, as well as Hong Kong and Macau residents entering Guangdong. This week, at a meeting of the national legislature, China's new premier, Li Qiang, urged greater effort to achieve a 5% growth target for the year.

Share This Post

Beijing, March 14, 2023: There is good news for patients travelling to China for advanced cancer treatment and the latest therapies like CAR T-Cell therapy, Cilta Cel therapy, and even for clinical trials in advanced cancer treatment. China will reopen its borders to foreign tourists on Wednesday for the first time since the outbreak of the COVID-19 pandemic three years ago by resuming the issuance of all types of visas.
The removal of this final border control measure imposed to combat COVID-19 comes after authorities declared victory over a recent outbreak of the virus last month.

The boost to the tourism industry should assist in reviving a $17 trillion economy that experienced one of its slowest growth rates in nearly half a century last year.

China’s foreign ministry announced on Tuesday that areas that did not require visas prior to the pandemic will again be visa-free. This includes the southern tourist island of Hainan and cruise ships docking at Shanghai port.

Hong Kong and Macau visa-free entry to the southern manufacturing hub of Guangdong will also be reinstated.

Foreign nationals with valid visas issued prior to March 28, 2020 will also be permitted to enter China, according to the ministry.

In January, China lifted its warning against foreign travel for its citizens and added 40 more countries to its list of countries where group tours are permitted, bringing the total to 60.

You may like to read: CAR T-Cell therapy in China

According to the Chinese flight tracking application Flight Master, the number of inbound and outbound international flights during the week of March 6 increased by more than 350% compared to the previous year, reaching nearly 2,500 flights. However, this number was still only 17.4% of 2019 levels.

In 2022, there were only 115,7 million border crossings into and out of China, with foreigners accounting for approximately 4.5 million.

In contrast, China recorded 670 million international trips in 2019, of which 97.7 million were made by foreigners.

Beijing abandoned its draconian zero-COVID policies in December, and quarantine requirements for incoming travellers were eliminated in January.

CAR T-Cell therapy in China has grown at a very rapid rate, and currently there are more than 750 clinical trials being conducted in China on different types of cancer. Clinical trials for advanced stage colon cancer is ongoing in some of the leading cancer hospitals in China.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy